Medical Device Clinical Study Strategy · FDA · EU MDR
There is no universally superior location for a medical device clinical study. The right model depends on the intended regulatory use of the data, the target population, clinical practice at the sites you would use, the endpoints, investigator and site availability, device and procedure maturity, realistic recruitment, operational complexity, and where you intend to commercialize. Geography is an evidence decision before it is a procurement decision, and it should be settled before the protocol and endpoints lock. This article compares the three models against the factors that actually change the answer.
Short answer
Most study-location discussions start with the wrong questions: which country is fastest, where the per-patient cost is lowest, or whether a European study can avoid an IDE. A better sequence starts with the evidence. What must the study prove, and to whom? Which population and clinical practice must the data represent? Which operating model can produce interpretable evidence rather than a dataset that has to be explained away later?
One point deserves to be stated plainly. A European clinical investigation is not a mechanism for avoiding applicable FDA requirements. FDA may accept information from a clinical investigation conducted outside the United States when the investigation is well designed and well conducted and the applicable conditions under 21 CFR 812.28 are met. Acceptance of that information is not automatic and does not by itself establish that the evidence is sufficient for the requested regulatory decision; relevance to the intended use, population applicability, clinical-practice comparability, endpoint alignment, device comparability, and submission-specific evidentiary expectations are addressed separately. Where material questions about the intended FDA use of the evidence remain unresolved, the sponsor should assess whether advisory FDA feedback is appropriate while the protocol and operating model can still be revised. The conditions are covered in detail in our article on FDA use of European clinical data.
Almost every program that touches both markets resolves into one of three operating models. A US-only study enrolls entirely within US practice and care settings. A Europe-led study generates its evidence at European centers, designed from the outset for its intended FDA and European uses. A hybrid study is a single study, or a coordinated program, with meaningful US and European participation under one aligned evidence strategy. The differences between them are evidentiary and operational, not ideological.
Model 1
A US-only model deserves serious assessment when the intended use is closely tied to US clinical practice; when the US standard of care or care setting materially affects the outcome being measured; when FDA has indicated that meaningful US enrollment is expected for your device and indication; when the relevant comparator exists mainly in the United States; when investigator adoption is itself commercially important; when the study must operate under an IDE; or when the sponsor already has the US site and operational capacity to run it well.
Principal advantages
Limitations and execution risks
These constraints are real, but each has a European counterpart, and the balance is device specific. The unresolved question for this model is usually whether European market access is also planned, and if so, what evidence will support it.
Model 2
A Europe-led model deserves assessment when the specialist investigators you need are available in Europe; when the European population is clinically applicable to your intended use; when the standard of care is comparable enough to support interpretation; when the sponsor also needs European clinical evidence for conformity assessment; when Europe can support first-in-human medical device studies in Europe or feasibility learning; and when the study can be prospectively designed for both its intended FDA and European uses. That last condition separates a Europe-led study that travels from one that does not: applicability to US practice is far easier to design in than to argue afterwards.
Principal advantages
Limitations and execution risks
Europe should not be selected on a promise of faster approval or lower cost. Neither claim is supportable without study-specific feasibility and budget work on the actual protocol. The unresolved question is whether prospective FDA feedback identifies material concerns about using the planned European evidence for its intended US purpose, and what changes or additional evidence may be needed.
Model 3
A hybrid study is not a US protocol translated for European sites; that is a US study carrying additional risk. A workable hybrid takes several shapes: majority European enrollment with selected US sites, European feasibility followed by US expansion, a US early feasibility study followed by a Europe-led or global pivotal, or a multinational pivotal built from common and jurisdiction-specific elements.
Principal advantages
Limitations and execution risks
Hybrid is valuable only when the additional geography adds evidence or execution value exceeding the complexity it creates. When the additional geography does not add sufficient evidence or execution value, it can increase complexity without improving the usefulness of the resulting evidence. The unresolved question is how each authority will view the regional mix, which should be discussed before endpoint lock.
Two groups of factors decide the answer far more reliably than headline timelines or site grants. The evidence factors define the question; the execution factors define whether a given model can answer it.
Evidence factors
Execution factors
Figure 1
Conceptual model shown as a diagram. The clinical and regulatory question sits at the center. A first stage of four evidence factors, intended use, population, practice, and endpoints, feeds a second stage of four execution factors, device maturity, sites and recruitment, operations, and budget. Together they resolve into one of three candidate output models: US-only, Europe-led, or hybrid.
Center
Clinical and regulatory question
Stage 1 · Evidence factors
Intended use
What the data must support, and where
Population
Who the evidence must represent
Practice
The care pathway around the device
Endpoints
What is measured, when, and by whom
Constrains
Stage 2 · Execution factors
Device maturity
Learning, training, and design stability
Sites and recruitment
Where the population is reachable
Operations
Jurisdictions, data, safety, logistics
Budget
Total program cost, not site price
Resolves to
US-only
Evidence question anchored in US practice
Europe-led
European sites can answer it, designed for intended use
Hybrid
Both settings add evidentiary value
A structured way to surface where the models diverge for your device. It is a discussion tool, not an algorithm, and it does not produce a regulatory conclusion.
| Criterion | US-only | Europe-led | Hybrid |
|---|---|---|---|
| Primary evidence objective | US applicability and FDA decision-making | European evidence, designed for its intended FDA and EU uses | Applicability across both settings |
| FDA relevance | Generated in US clinical settings, but relevance still depends on the device, intended use, design, endpoints, conduct, and submission | Potentially relevant where US applicability is designed prospectively and the evidence plan is discussed with FDA where material | Includes US representation; pooling, heterogeneity, and regional effects should be addressed prospectively |
| EU MDR relevance | Limited without European clinical data | Direct | Direct |
| Population applicability | US practice setting; representativeness still depends on the design and enrolled population | Depends on comparability to the intended US use | Broadest, at the price of heterogeneity |
| Standard-of-care comparability | Not at issue for US use | Must be assessed and controlled in the protocol | Must be harmonized or analyzed as a regional effect |
| Operational complexity | One jurisdiction, high per-site burden | Multicountry start-up and coordination | Highest: parallel pathways and safety reporting |
| Regional learning value | US operator and adoption learning | European operator and market learning | Both, where the program can absorb it |
| Principal risk | Cost, recruitment, and site concentration | US applicability questioned late | Complexity outweighing the evidence gained |
Table scrolls horizontally on narrow screens.
Figure 2
Diagram with three aligned lanes. Route one runs from a US-only study to a US evidence review to a pivotal or submission decision. Route two runs from a European study to an applicability assessment to an FDA and EU development decision. Route three runs from US and European sites to a harmonized data review to jurisdiction-specific evidence packages. A shared band below lists the central functions common to all three routes.
Route 1 US-only
US-only study
Enrollment in US practice and care settings
US evidence review
Performance, safety, and operator learning
Pivotal or submission decision
European evidence needs addressed separately
Route 2 Europe-led
European study
Enrollment at selected European centers
Applicability assessment
Population, practice, endpoints, and conduct tested against intended use
FDA and EU development decision
Bridging needs identified with the authorities
Route 3 Hybrid
US and European sites
One aligned evidence strategy
Harmonized data review
Pre-specified assessment of regional effects
Jurisdiction-specific evidence packages
Assembled from one dataset, not identical documents
Shared central functions across all three routes
Written to show how the factors interact. They are hypothetical illustrations, not Eclevar case studies, and no client program is described.
Scenario A
Scenario B
Scenario C
Illustrative scenarios only. The appropriate pathway requires device-specific regulatory, clinical, and operational assessment.
For US sponsors
If the assessment points to a Europe-led or hybrid model, the next question is delivery: countries, sites, submissions, monitoring, data, and reporting under one accountable partner.
These items must be settled before the first submission, because each one is expensive to change afterwards.
Eclevar is a specialist medical device CRO with former Notified Body reviewers in its clinical leadership. When a Europe-led or hybrid model is selected, we deliver the European component and connect it to the sponsor's broader US-Europe evidence strategy.
Where US regulatory leadership sits with the sponsor or a designated FDA specialist, Eclevar can connect that strategy to European study design and execution, so the two are built as one evidence plan rather than reconciled afterwards.
Where we contribute
This article draws on ECLEVAR’s European clinical strategy expertise and contributions from its clinical leadership and external US clinical operations advisor. It provides general strategic information, not regulatory advice for a specific device or submission.
Chief Operating Officer and Head of Cardiovascular, Senior Consultant Surgeon
Mark leads cardiovascular clinical strategy, combining 25 years of Consultant Cardiac Surgery experience with first-hand senior leadership Notified Body experience.
Chief Medical Officer, Orthopedics and Spine, Senior Consultant Surgeon
Nikhil is an orthopedic surgeon and former Notified Body clinical reviewer. He contributes a clinical and operator perspective on study design, endpoint selection, learning curves, and the interpretation of evidence for implantable and procedural devices.
LinkedIn profile
Strategic Clinical Advisor, US Clinical Operations
External strategic advisor to ECLEVAR MedTech. Dawn contributes a US clinical operations perspective on study planning, site and investigator considerations, operational feasibility, and execution interfaces between US and European clinical programs.
Her own professional background includes approximately 15 FDA Pre-Submission and Q-Submission interactions, more than 10 years of IRB coordination, IDE conditions of approval, IDE supplements, protocol and device changes, sponsor reporting under 21 CFR Part 812, and BIMO inspections, together with three years managing an early feasibility study and support to pilot-study submissions. On any sponsor program, US regulatory leadership remains with the sponsor’s FDA regulatory lead or a separately retained qualified FDA specialist.
LinkedIn profileMeet the full clinical leadership on our executive team page. Explore relevant medical device programs in our Client Success Stories.
Next step
Choosing between a US-only, Europe-led, or hybrid model requires a device-specific review of the intended regulatory use, population, endpoints, sites, operational constraints, and existing evidence. Eclevar's US-Europe Clinical Strategy service converts those inputs into a documented study-model recommendation and European execution plan.
Official content
Whitepapers, client voices and publications produced by our own teams and by our partners: BSI, TÜV SÜD and RegenLab.
Whitepaper · BSI x Eclevar
Written with the notified body BSI: a practical look at what clinical evidence has to show under EU MDR 2017/745, and at the quality bar the data have to clear. It is the same bar a European dataset meets before it is put in front of any reviewer.
PMCF studies · Regenerative medicine · 5 EU countries
Eclevar runs RegenLab's PMCF program on chronic wound products. It is a randomized study of 160 subjects across 14 centers in 5 EU countries, covering both diabetic foot ulcer and venous leg ulcer. The partnership combines Eclevar's ISO 14155 expertise with the Milo Studio platform, from study design through to the final study report.
« Eclevar, with its tailored approach and the advanced Milo Studio platform, represents a significant strategic advantage. »Antoine Turzi, CEO, RegenLab
Coming soon. Breakthrough Device Technology under the EU MDR, a whitepaper written with TÜV SÜD, co-authored by Dr Nikhil Khadabadi.
It can, under conditions. FDA may accept information from a clinical investigation conducted outside the United States when the investigation is well designed and well conducted and the applicable conditions under 21 CFR 812.28 are met. Acceptance of that information is not automatic and does not by itself establish that the evidence is sufficient for the requested regulatory decision. Separate evidentiary considerations then apply, distinct from those acceptance conditions: relevance to the intended use, population applicability, clinical-practice comparability, endpoint alignment, device comparability, and submission-specific evidentiary expectations. Where material questions about the intended FDA use of the evidence remain unresolved, the sponsor should assess whether advisory FDA feedback is appropriate while the protocol and operating model can still be revised.
There is no universal requirement for US enrollment. FDA evaluates the evidence in the context of the particular device, intended use, investigation, and submission. For a premarket approval application relying solely on foreign clinical data, 21 CFR 814.15 includes the specific consideration that the data be applicable to the US population and US medical practice. Whether US enrollment is expected for a particular program should be addressed with FDA where the question is material.
A single study, or a coordinated program, with meaningful US and European participation under an aligned evidence strategy. It is not a US protocol translated for European sites. A workable hybrid needs common definitions, harmonized assessments, one safety framework, and a pre-specified approach to regional effects, and its value depends on the additional geography adding more evidence than the complexity it creates.
No. Some programs reach first participant sooner in Europe; others do not. Timing depends on protocol readiness, authority and ethics review in the selected countries, contracting, insurance, device availability, training, and recruitment. On cost, site grants are one component of a program budget: multicountry submissions, translations, logistics, and data harmonization can offset lower per-patient costs, and delays in submissions, contracting, activation, recruitment, or follow-up can materially affect the total program cost in any geography.
Where material questions about geography, population applicability, endpoints, study design, or the intended FDA use remain unresolved, the sponsor should assess whether FDA feedback is appropriate while the protocol and operating model can still be revised. A Pre-Submission is one mechanism within FDA's Q-Submission Program; its timing depends on the device, pathway, development stage, prior interactions, and the questions being asked. The feedback is advisory and does not constitute approval or guarantee IDE approval, clearance, approval, or acceptance of the proposed evidence. It provides a formal route for obtaining FDA feedback while important design assumptions may still be revised.
Device description and intended use, development stage, target population, proposed endpoints, intended FDA and European pathways, existing preclinical and clinical evidence, investigator relationships, candidate countries, estimated sample size, target timeline, and the principal uncertainty to be resolved. With that set, a structured and device-specific comparison of the three models is possible; without it, any comparison stays generic.
